Skip to main content

Biogen

Biogen Inc. is an American biopharmaceutical enterprise focusing on the discovery, development, and delivery of therapies for neurological conditions. The company conducts operations under a single biopharmaceuticals business segment dedicated to neurodegenerative diseases. Its commercial drug portfolio includes therapies for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, and Alzheimer's disease. Revenue generation is primarily driven by global prescription sales of specialty pharmaceuticals and royalty payments from collaborative agreements. The firm maintains a prominent market-leading position in neurology and clinical neuroscience research. Biogen is headquartered in Cambridge, Massachusetts, United States, and trades on the NASDAQ.

50 of the funds FundTelligence covers report a position in Biogen.

Legal name
Biogen Inc
Sector
Health Care
Country
United States
Funds holding it
50
Exposure themes
Multiple, Treatment, Women's Health, Ageing & Longevity, Age-Related Disease, Neurodegeneration

Funds holding Biogen

Showing the 8 largest of 50 funds holding it.

Loading...